Healthcare Industry News: bladder cancer
News Release - May 1, 2007
diaDexus Announces Two Key Executive AppointmentsSOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--diaDexus, Inc., a privately held biotechnology company and developer of the PLACŪ test, today announced two executive appointments. David Foster has been named Chief Financial Officer (CFO) and Executive Vice President, and Dino Alfano has been appointed Executive Vice President, Sales and Marketing.
As CFO, Foster will oversee financial and administrative functions for diaDexus and will work closely with other members of the company's senior management team in setting overall corporate direction. Most recently, Foster served as CFO of Argonaut Technologies, a publicly owned chemical instrument and consumables company. He also was co-founder and Chief Executive Officer of Cohesion Technologies and worked for several years at Collagen Corp., including four years as CFO.
Alfano has significant experience building early stage companies. Previously, he was President of Iris Diagnostics, a subsidiary of Iris International. At Iris Diagnostics, Alfano was instrumental in growing sales from $30 million in 2003 to $70 million in 2006, and expanding distribution from three to 60 countries. He also has served as Vice President, Business and Product Development, at Oxibio, and as Vice President, Global Sales and Marketing, at Litmus Concepts, two early stage biotech companies. Earlier in his career, Alfano helped build the bladder cancer testing market with Bard Diagnostics, and while at Syva Company, he led European marketing for its therapeutic drug assay lines. Alfano will direct commercial operations for diaDexus.
According to Patrick Plewman, President and Chief Executive Officer of diaDexus, these new executives will play a critical part in the company's growth as demand continues to increase for the PLAC test, a novel cardiovascular assay. "We are pleased to welcome David and Dino to diaDexus," Plewman said. "Both have been instrumental in building medical technology and diagnostics companies and have a deep understanding of our business. As members of the senior executive team, they will play key roles helping diaDexus grow as physicians and clinical laboratories increasingly recognize the value of the PLAC test in identifying individuals at risk for coronary heart disease and stroke."
diaDexus, Inc., based in South San Francisco, is focused on the discovery, development, and commercialization of innovative, patent-protected diagnostic products with high clinical value. The PLAC test is a simple blood test that measures a new risk factor for coronary heart disease and stroke-lipoprotein-associated phospholipase A2 (Lp-PLA2), a cardiovascular-specific inflammatory marker implicated in the formation of vulnerable, rupture-prone plaque. The PLAC test has been cleared for marketing by the Food and Drug Administration as an aid in determining risk for coronary heart disease and ischemic stroke associated with atherosclerosis. In addition to the PLAC test, diaDexus is developing a pipeline of novel cancer diagnostic tests. For more information, visit www.plactest.com or www.diaDexus.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.